Skip to main content
 

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept

 
News

BeiGene News

See all News

  • July 2, 2020
    BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research

    BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research

  • July 1, 2020
    BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China

    BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China

  • July 1, 2020
    BeiGene Announces Appointment of Angus Grant as Chief Business Executive

    BeiGene Announces Appointment of Angus Grant as Chief Business Executive

  • June 30, 2020
    BeiGene Begins Commercializing XGEVA® (Denosumab) in China

    BeiGene Begins Commercializing XGEVA® (Denosumab) in China

  • June 22, 2020
    BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial

    BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial

  • June 19, 2020
    BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China

    BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China

  • BeiGene Facts
  • 2010Founded
  • NASDAQ: BGNE  
    HKEX: 06160
    Listings
  • 6Internally Developed
    Clinical Candidates
  • 3Marketed
    Products
    in China
  • 1Approved
    products
    in the U.S.
  • 3000+Global Team
story
 
  • 2010

    • BeiGene was founded as a research and development company
    BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.
  • 2012

    • Began work on an anti-PD-1 antibody and a BTK inhibitor
    Immuno-oncology Therapies
  • 2014

    • Started clinical trials of pamiparib and zanubrutinib
    Clinical Researcher
  • 2016

    • Went public on the Nasdaq, with $182 million initial public offering
    First China biotech to go public on the Nasdaq
  • 2018

    • Established first European office in Switzerland
    • 50+ ongoing or planned clinical trials
    BeiGene expands global operations
  • 2019

    • Received first FDA approval for BRUKINSA™ (zanubrutinib)
    • Received first approval for tislelizumab in China
    2019

Our Story

Breaking Boundaries From the Beginning

From our start in Beijing with a handful of scientists and developers, to today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have accomplished so much in a short time, and yet there is so much still to do.

Our Story

Partnering

Partnerships that Extend Around the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships.

Partners

ZymeworksBioAtla LogoLeapSeattleAmbrx LogoMirati LogoMei PharmaAmgen logo

Our Patients

Our Commitment to Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers